

<b>Date and Time:</b>	<b>5th October 2012, 10.00 – 17.00 hrs</b>
-----------------------	--

<b>Minutes:</b>	
<b>11th Guideline Development Group Meeting</b>	
<b>Place:</b>	National Clinical Guidelines Centre, 180 Great Portland Street, Boardroom
<b>Present:</b>	<p>Nik Hirani (<b>Chair</b>)  Ann Millar(via teleconference)  Angela Key  Annette Duck  Malcolm Weallans  Nicholas Kim Harrison  Patrick Wilson (via teleconference)  Tessa Lewis</p> <p>Emmert Roberts, Research Fellow (am only)  Izaba Younis, Research Fellow  Zahra Naqui, Research Fellow  Vicki Pollit, Acting Senior Health Economist  Nina Balachander, Senior Research Fellow and Project Manager  Vanessa Delgado Nunes, Guideline Lead</p>
<b>In attendance:</b> Jaimella Espley, NICE Editor Clifford Middleton, NICE Guidelines Commissioning Manager	
<b>Apologies:</b> Geraldine Burge Melissa Hippard Nick Sreaton Richard Hubbard Sue Copley	

**Notes**

<p>1. Nik Hirani welcomed the group to the eleventh GDG meeting. Apologies were received from. The Chair asked all GDG members to declare any relevant conflicts of interest.</p> <p><i>NH declared a personal non-pecuniary interest. NH attended an IPF meeting, ICLAF, in Italy, from the 29<sup>th</sup> September to 4<sup>th</sup> October 2012. NH also published an abstract in the ERS journal. No financial remuneration was received for either of these declarations.</i></p> <p><i>AD declared personal pecuniary interests. AD acted as a freelance trainer on the ARNS ILD study day in Belfast for which she received trainer fee of £300.00. AD was also involved in a radio interview on South Manchester radio for which there was no financial remuneration. AD declared a personal non-pecuniary interest, as she was involved with IPF awareness week sponsored by Intermune, which paid £500.00 to the hospital department where AD works.</i></p> <p><i>MW declared a personal non-pecuniary interest. MW is attending a research day at the Brompton, which is funded by Intermune, but for which MW does receive any financial</i></p>
--

## Notes

remuneration. MW is also attending the Pirfenidone technology appraisal meeting in Manchester on the 24<sup>th</sup> October, for which travel expenses are funded by NICE.

PW declared a personal pecuniary interest. PW attended training on “Negotiating and Influencing”, which was paid for by Bayer Pharmaceuticals.

VN declared a non-personal non-pecuniary interest. VN is attending the Pirfenidone technology appraisal meeting in Manchester on the 24<sup>th</sup> October. No financial remuneration is being received for this.

There were no changes in any of the other GDG members’ or NCGC staff’s DOIs since the last meeting.

No actions were taken following these declarations and none of the GDG members withdrew as none of the declarations conflicted with clinical areas to be discussed during the GDG meeting.

### **Presentations:**

Each of the following presentations were given:

1. Update on HE model – VP
2. Re-run searches – ER, ZN, IY
  - a. update of evidence including addition of new studies
  - b. amendments to recommendations
3. Full recommendations review - NB
  - a. to agree content
  - b. identify gaps in the care pathway
  - c. review algorithm for diagnosis and management
4. Key priorities for implementation - discussion with GDG and prioritisation - NB
5. Research recommendations: - finalise wording and prioritisation - NB
6. Workplan - NB

1. VP presented an update on the economic model for pulmonary rehabilitation and informed the GDG that work is still ongoing to validate the model. The GDG considered the evidence presented from randomised trials and reviewed previous recommendations made.
2. ER, ZN and IY presented the results of the re-run searches and informed the GDG of new studies included the relevant evidence reviews as a result of these searches. A summary of the new studies included was presented alongside a recap of evidence presented at previous GDG meetings. The GDG considered the evidence presented and reviewed previous recommendations made.
3. The GDG revised previous recommendations developed so far taking into account suggestions by the NICE Editor and also viewed the algorithms for diagnosis and management in IPF patients.

The session on reviewing recommendations overran, so it was decided that the key priorities for implementation, algorithms, research recommendations and workplan would be discussed between GDG meetings.

### **Any other business:**

None

## Notes

**Date, time and venue of the next meeting:**  
**GDG 12:** Thursday 1<sup>st</sup> November, RCP Censors Room.